BioSpace News Archive

Sensorium Therapeutics today announced the appointment of veteran life sciences executive David Southwell to its Board of Directors.

Spinogenix, Inc., a clinical-stage biopharmaceutical company developing novel small molecule drugs for neurological conditions, announced a second grant award by the National Institute of Health.

Pierre Fabre Laboratories , the French pharmaceutical and dermo-cosmetic company, announced the acquisition of Vertical Bio AG, a developer of novel cancer therapies.

Mission Bio, a leader in single-cell multi-omic solutions for precision medicine, today launched the Tapestri® Genome Editing Solution.

A new agreement is poised to accelerate antibiotic access for tens of thousands of patients in regions with the highest rates of antimicrobial resistance.

CorVista Health, Inc., a leading digital health company dedicated to improving cardiovascular disease diagnosis, is pleased to announce the FDA clearance of the CorVista System® with CAD Add-On to evaluate the presence of significant coronary artery disease as an aid in diagnosis.

Ferring Pharmaceuticals announced the first patient in the United States with high-risk Bacillus Calmette-Guérin -unresponsive non-muscle invasive bladder cancer was dosed with the commercially available intravesical gene therapy ADSTILADRIN® as part of the ADSTILADRIN Early Experience Program announced earlier this year.

Bausch Health Companies Inc. is pleased to announce that following its approval by Health Canada the new treatment PrUCERIS® aerosol foam is now available across Canada to treat mild to moderate distal ulcerative colitis in adults.

FibroBiologics, a clinical-stage biotechnology company focused on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, announced the dedication of its cutting-edge laboratory facility as the Newlin-Linscomb Lab for Cell Therapeutics, within the University of Houston Innovation Center.

Myeloid Therapeutics, Inc. (“Myeloid”), a clinical stage oncology company, has dosed the first patient with MT-302 in a Phase 1 study for advanced or metastatic epithelial tumors.